WHO, NCEP-ATP III, and IDF screening criteria were compared in another very large population-based study of 10,592 men 50 to 59 years of age from France and Belfast (Southern and Northern Europe) followed for 5 years (6). Entitled the prospective epidemiological study of myocardial infarction-étude PRospective de l’Infarctus du MyocardE (PRIME), it involved a nested case-control study cohort that matched 296 cases of coronary heart disease (CHD) to 540 CHD-free controls according to age, recruitment centre, and date. Metabolic syndrome prevalence was 36%, 30%, and 39% in cases and 29%, 23%, and 32% in controls according to WHO, NCEP-ATP III, and IDF clinical criteria, respectively. The corresponding ORs for future CHD were 1.40 (95% CI, 1.01-1.94), 1.46 (95% CI, 1.04-2.04), and 1.41 (95% CI, 1.02-1.95).

Role of the Dysregulated Endocannabinoid System in Determining Cardiometabolic Risk by Vincenzo Di Marzo, PhD
More
What is the role of low HDL cholesterol in the elevated CHD risk of metabolic syndrome patients? By Philip J. Barter, MBBS, FRACP, PhD
More
Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond) 2008;32:283-91
More
Schematic representation of how smoking might add to several mechanisms linking obesity to cardiovascular disease
More